Michael Kring, Chairman of the Advisory Board
Michael Kring is CEO of High Tech Corporate Services; Munich, a consulting company providing operational financial consulting services to high technology companies. He is a renowned expert in the field of finance and structuring of young start-up Biotech companies. He and his team have set up more than 100 start-up companies in Germany in the past 10 years.
Prof. Hans-Georg Rammensee, Founder
Prof. Rammensee is head of the Department of Immunology at the University of Tübingen. His outstanding scientific reputation is based upon ground-breaking work on peptide/MHC interactions and on therapeutic peptide- and RNA-based vaccines. He is co-founder of Immatics Biotechnologies GmbH and CureVac GmbH, two companies developing anti-tumour vaccines on peptide and RNA basis, respectively.
Representative of Synimmune Equity Ltd.